Serum xenopsin-related peptide-1 levels in pregnant women with hyperemesis gravidarum; a cross-sectional study

OBJECTIVE: To investigate serum xenopsin-related peptide (XRP) -1 levels in women with hyperemesis gravidarum (HEG) from the onset of pregnancy until the end of week 14. MATERIALS AND METHODS: This cross-sectional study was conducted at the Antalya Training and Research Hospital Obstetrics Clinic, Türkiye, between July and December 2024. Forty-five pregnant diagnosed with HEG and 45 healthy pregnant were included. Venous blood samples for the XRP-1 test were collected from pregnant women and the collected serum samples were stored at -80 degrees until the day of analysis. RESULTS: Significant differences were observed between the HEG and healthy groups in terms of serum thyroid-stimulating hormone (1.86 ± 0.54 vs. 1.38 ± 0.67, respectively, p = 0.027), potassium (3.84 ± 0.45 vs. 3.58 ± 0.60, p = 0.010), and XRP-1 (4.33 ± 1.66 vs. 2.38 ± 1.32, p < 0.001) values. At receiver operating characteristic analysis, the area under the curve (AUC: 0.824) was statistically significant for serum XRP-1 (p < 0.001), with a cut-off value of ≥ 2.42 [95% confidence interval 0.731-0.917, 82.2% sensitivity, and 80.0% specificity]. The positive predictive value of serum XRP-1 was 80.0% and the negative predictive value was 81.0%. CONCLUSION(S): This study suggests that serum XRP-1 levels are elevated in HEG. Further studies are now needed to validate these findings.